Answers are grounded in this paper and cite their sources.
Periodontitis is a chronic inflammatory disease caused by a dysbiotic subgingival biofilm that triggers an imbalanced host immune response. This study developed and evaluated poly(lactic-co-glycolic acid) (PLGA) nanoparticles co-loaded with doxycycline (DOX) and resveratrol (RV) for dual-action periodontal therapy. Nanoparticles were prepared by double-emulsion solvent evaporation and characterized for size, charge, encapsulation efficiency, release kinetics, antimicrobial activity, cytocompatibility, and osteogenic effects in vitro and in vivo. The co-loaded nanoparticles (PLGA-DOX/RV) had a mean size of 256.6 ± 13.4 nm, zeta potential of −17.3 ± 2.2 mV, and encapsulation efficiencies of 94.6% (DOX) and 95.8% (RV). In vitro release showed a biphasic profile, with cumulative release reaching 67.6% and 75.9% at 72 h, respectively. PLGA-DOX/RV reduced minimum inhibitory and bactericidal concentrations fourfold against P. gingivalis and A. actinomycetemcomitans, and inhibited biofilm formation by >55%. Cytotoxicity assays indicated 65.3% fibroblast viability at 200 µg/mL, while alkaline phosphatase activity increased by 67.3%. In vivo, PLGA-DOX/RV reduced alveolar bone loss (0.65 mm vs. 0.89 mm in control) and lowered IL-1β, IL-6, and TNF-α by 67.4%, 80.1%, and 74.2%, respectively. These results demonstrate PLGA-DOX/RV as a potent localized therapy for periodontitis.
No takes yet. Share an insight, caveat, or question.
Alavi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: